Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 6/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043609 | 0.83 | ATR (0.44) | ATRLCKCA1PI4KB | |
| SCHEMBL23960262 | 0.82 | LMNA (0.42) | ATRLCKCA1CA2PSMB8 | |
| SCHEMBL23960257 | 0.81 | ATR (0.40) | ATRLCKCA1CA2PSMB8 | |
| SCHEMBL23960254 | 0.81 | ATR (0.40) | ATRLCKCA1CA2CYP17A1 | |
| SCHEMBL23927246 | 0.79 | ATR (0.56) | ATRLCKCA1CA2 | |
| SCHEMBL23960309 | 0.79 | ATR (0.41) | ATRLCKCA1CA2CYP17A1 | |
| SCHEMBL23960341 | 0.79 | ATR (0.44) | ATRLCKCA1CA2CYP17A1 | |
| SCHEMBL23960284 | 0.79 | ATR (0.43) | ATRLCKCA1CA2PSMB8 | |
| SCHEMBL7209947 | 0.76 | ATR (0.46) | ATRLCKCA1CA2CYP17A1 | |
| SCHEMBL14341595 | 0.75 | METAP1 (0.40) | ATRLCKCA1CA2PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901151-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | ATR 1763/4885LCK 72/4885CA1 4698/4885 |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | ATR 1283/4885LCK 122/4885CA1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.